Biosimilars use in Europe

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

Biosimilars use in Europe

Home/Reports | Posted 25/11/2011 2 Post your comment

A legal framework for approving biosimilars in the EU was established in 2003 and guidelines for an abbreviated registration process were issued in 2006. However, acceptance and use of biosimilars within Europe varies by country.

The European legal framework means that biosimilars can only be approved centrally via EMA and not nationally. EMA, however, does not make any decision on interchangeability of biosimilars for the originator product; this is made at a national level.

EMA approved the first biosimilar for somatropin (Omnitrope) back in 2006. To date the agency has approved 14 biosimilars for use in the EU, within the product classes of human growth hormone (HGH), granulocyte colony-stimulating factor (G-CSF) and erythropoietin [1].

Some countries, however, have seen only a minor adoption of these biosimilars while others now have biosimilars accounting for the majority of market share for certain therapeutic categories.

Countries with high acceptance of biosimilars include Austria, Germany and Sweden. Germany, in fact, has some of the highest market shares in Europe based upon the implementation of quotas for biosimilar prescribing by physicians, see Table 1. UK, on the other hand, while it has relatively low acceptance of HGH and erythropoietin biosimilars, has the highest level of G-CSF use in Europe.

Table 1: Use of biosimilars in Europe

Country	Biosimilar share of originator sales (March 2011)
Country	HGH (Q2 2006)* One biosimilar	Erythropoietin (Q3 2007)* Five biosimilars	G-CSF (Q3 2008)* Six biosimilars
Austria	6%	50%	52%
France	20%	11%	42%
Germany	12%	65%	45%
Greece	N/A	67%	53%
Italy	12%	7%	18%
Poland	7%	62%	38%
Romania	34%	58%	77%
Spain	15%	16%	24%
Sweden	21%	63%	45%
UK	4%	9%	80%
EU total	13%	18%	38%

*EU approval date; HGH: human growth hormone; G-CSF: granulocyte colony-stimulating factor; N/A: not applicable.
Source: IMS MIDAS//MTA Global Database: March 2011, Monthly Sales, Units

It is clearly understood that biosimilars cannot directly substitute the originator products. However, EMA sets high standards for safety and efficacy, which should reassure clinicians and enable them to prescribe biosimilars instead of the originator products.

Erythropoietin biosimilars lead the way as their effects are visible immediately and uptake is therefore good in many countries. One reason for the low uptake of HGH biosimilars in most countries could be due to the fact that it is given primarily to children and effects are visible only over the longer term, so tolerance of risk and reduced efficacy may be lower.

Related article

Market opportunities for biosimilars

Reference

1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in Europe [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2011 November 25]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe

Source: Novation

Comments (2)

Post your comment

Posted 05/08/2013 by Jodi H, GaBI Online Editorial Office

Response to ‘Quota for biosimilars prescribing will be key driver in increasing biosimilar uptake’

Dear Dr Pramanik,
Thank you for your comment. Please note that we will soon publish such an article in GaBI Journal. Please visit www.gabi-journal.net to keep a look out for upcoming manuscript topics.
Best regards,
Jodi

Posted 10/07/2013 by Kallal Pramanik, PhD

Quota for biosimilars prescribing will be key driver in increasing biosimilar uptake

The quota's on biosimilar prescribing will be one of the key driver for increasing biosimilar uptake. Can anyone shed more light on prevalence of such quota system in European countries. One article on such topic will be very interesting.